Prokidney Corp PROK.OQ PROK.O is expected to show a rise in quarterly revenue when it reports results on March 13 (estimated) for the period ending December 31 2025
The Winston-salem North Carolina-based company is expected to report revenue of $150 thousand, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Prokidney Corp is for a loss of 12 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Prokidney Corp is $7.00, about 182.3% above its last closing price of $2.48
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.12 | -0.13 | -0.12 | Beat | 9.1 |
Jun. 30 2025 | -0.13 | -0.14 | -0.13 | Beat | 9.7 |
Mar. 31 2025 | -0.16 | -0.16 | -0.13 | Beat | 17.5 |
Dec. 31 2024 | -0.15 | -0.15 | -0.17 | Missed | -14.5 |
Sep. 30 2024 | -0.14 | -0.15 | -0.14 | Beat | 4.1 |
Jun. 30 2024 | -0.17 | -0.17 | -0.16 | Beat | 6.6 |
Mar. 31 2024 | -0.18 | -0.18 | -0.16 | Beat | 10.6 |
Dec. 31 2023 | -0.14 | -0.17 | -0.09 | Beat | 47.2 |
This summary was machine generated March 11 at 11:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments